India Pesticides Reports Strong Q1 FY26 Growth, Revenue Up 25.8% YoY with Positive Outlook
The announcement details substantial financial growth in Q1 FY26, including a 25.8% revenue increase and 79.2% PAT growth. It also outlines significant capital expenditure plans (₹116 crore for FY26) for capacity expansion and new product development, which are expected to drive future revenue and profitability, as evidenced by the ₹1,000 crore revenue target for FY26.
The company reported strong Q1 FY26 financial performance with significant year-on-year growth in revenue (25.8%), EBITDA (62.6%), and PAT (79.2%), along with improved margins. Management provided positive guidance for FY26 and FY27, backed by successful capacity expansions and a pipeline of new product launches.
India Pesticides Limited announced robust financial results for Q1 FY26, highlighting significant growth across key parameters and outlining strategic expansion plans: * Financial Performance (Q1 FY26): * Total revenue reached ₹282 crore, marking a 25.8% year-on-year (YoY) increase and 34% quarter-on-quarter (QoQ) growth. * EBITDA stood at ₹52 crore, up 62.6% YoY, with EBITDA margin expanding to 18.4% (up 4.17% YoY). * Net profit increased by 79.2% YoY to ₹35 crore, achieving a PAT margin of 12.3% (up 3.6% YoY). * Return on Capital Employed (ROCE) improved to 18.34% from 14% in the previous year. * Revenue Mix: * Exports contributed ₹87 crore (vs ₹77 crore in Q1 FY25), while domestic revenue was ₹188 crore (vs ₹143 crore in Q1 FY25). * Revenue from technicals was ₹194 crore and formulations was ₹81 crore. The herbicide business saw robust growth, particularly Pretilachlor, benefiting from anti-dumping duties and increased capacity. * Operational & Capacity Expansion: * The expanded intermediate PEDA facility was commissioned, increasing capacity from 2,000 tons to 6,000 tons per annum, with a further scale-up to 8,500 metric tons per annum on track for Q2 FY26. * Formulation capacity was augmented by 3,500 MT per annum. * R&D efforts have led to the development of several new molecules. * Capex & Future Guidance: * The company plans a capital expenditure of approximately ₹116 crore for FY26 (₹52 crore for existing facilities and ₹64 crore for its wholly-owned subsidiary, Shalvis Specialties Ltd. in Hamirpur, Uttar Pradesh). * Management targets a revenue of ₹1,000 crore for FY26 with an EBITDA margin between 18%-20%. * For FY27, a growth of 15%-20% in revenue is envisaged, maintaining EBITDA margins between 18%-20%. * New product launches are in pipeline for FY26 and onwards, including two products for IPL and three for Shalvis Specialties Ltd. * Combined PEDA and Pretilachlor sales are targeted at ₹150 crore for the current fiscal year and ₹250-₹300 crore for FY27, expecting 70%-75% utilization of the augmented capacity. * Interest costs are expected to reduce in subsequent quarters due to liquidation of inventory and lower working capital limits. * Management Comments: * Mr. Vishwas Swarup Agarwal, Non-Executive Director, stated that the company demonstrated resilience and strong performance despite global headwinds, emphasizing focus on manufacturing scale-up, R&D, and a differentiated product portfolio. * Mr. D. K. Jain, CEO, highlighted early signs of recovery in the global agrochemical market, normalized inventory levels, and stable raw material prices, expressing optimism for FY26 and beyond. * Mr. S. P. Gupta, CFO, confirmed a strong balance sheet and the company's plan to fund its Capex primarily through internal accruals.
What to do with a filing like this
India Pesticides Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Pesticides Limited. Read the original for the full detail.